
    
      Cohorts 2, 3, and 4 will be on a boosted protease inhibitor (PI) or any other 3rd
      antiretroviral (ARV) agent and will switch their current 2-NRTI-containing regimen to
      open-label F/TAF while continuing their boosted PI or 3rd agent through 48 weeks. A minimum
      of 10 participants each in Groups 1 and 2 of Cohort 2, and Cohorts 3 and 4, who are on
      boosted-atazanavir (ATV) as their 3rd ARV agent will be enrolled. Participants in Cohort 2,
      Group 1 receive boosted PI agents only. Cohorts 2, 3, and 4 will be enrolled by cohort into a
      two-part study (Parts A and B).

      After completion of 48 weeks, all participants will be given the option to participate in an
      extension phase of the study. Gilead will provide F/TAF until a) The participant turns 18
      years old and F/TAF is commercially available for use in adults in the country in which the
      participant is enrolled or b), F/TAF becomes commercially available for pediatric use in the
      country in which the participant is enrolled or c), Gilead Sciences elects to terminate
      development of F/TAF in the applicable country.
    
  